SOLAI Limited vs Tilray Brands Inc — how do they compare? SOLAI Limited trades at $3.72 (market cap $880.09M), while Tilray Brands Inc trades at $3.48 (market cap $530.54M). The key difference: SOLAI Limited is the larger of the two by market cap, and SOLAI Limited is more actively traded (122,720 versus 9,099,075). Which is the better fit depends on your goals — on Pluang, investors hold SOLAI Limited for 40 Days and Tilray Brands Inc for 31 Days on average.
| SLAI | TLRY | |
|---|---|---|
Market Cap | $880.09M | $530.54M |
Volume | 122,720 | 9,099,075 |
Sector | Technology | Health |
52-Week High | $21.63 | $21.00 |
52-Week Low | $2.74 | $3.57 |
Typical Hold Time | 40 Days | 31 Days |
Enterprise Value | $879.73M | $684.46M |
Signals from Pluang's Aura AI — not financial advice
SLAI trades at $3.72 with no recent price movement. The technical picture is bullish based on moving averages and oscillators, though the stock faces delisting proceedings from the NYSE. Fundamentally, the company shows severe distress with negative gross and net income margins, high revenue decline, and substantial losses despite a low P/B ratio. Recent news highlights governance changes amid exchange compliance issues.
The outlook is highly risky due to financial instability and delisting threat. Investment opportunity exists only for speculative traders betting on a turnaround, given the low valuation multiple. Key risks include continued cash burn, inability to achieve profitability, and loss of major exchange listing impacting liquidity and investor confidence.
TLRY trades at $3.465, down 6.73% on the day and near 52-week lows, reflecting persistent bearish sentiment. The stock shows weak technical momentum with oversold RSI readings but faces fundamental challenges including consecutive quarterly earnings misses, negative profit margins, and declining revenue growth. Recent news highlights the company's struggles with profitability despite record annual revenue, with shares down over 50% year-to-date as investors question the cannabis company's path to sustainable growth.
TLRY presents a high-risk opportunity with significant downside protection from its low P/B ratio of 0.33, but requires substantial operational improvement to justify investment. The bullish case hinges on potential marijuana reform catalysts and BrewDog integration progress, while risks include ongoing losses, competitive pressures, and execution challenges in a volatile regulatory environment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →